INSULIN SECRETION, REGULATION, AND THE EPIDEMIOLOGY, CLASSIFICATION, CLINICAL FEATURES, AND DIAGNOSIS OF TYPE 1 AND TYPE 2 DIABETES MELLITUS: A GLOBAL PERSPECTIVE
DOI:
https://doi.org/10.55640/Keywords:
Diabetes mellitus; Insulin secretion; Insulin resistance; Type 1 diabetes; Type 2 diabetes; Epidemiology; β-cell dysfunction; Hyperglycemia; Diagnosis; Public health burden.Abstract
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to defects in insulin secretion, insulin action, or both. Its global prevalence has risen sharply in recent decades, making it a major public health concern. Insulin, produced by pancreatic β-cells, regulates glucose homeostasis through complex mechanisms involving glucose sensing and calcium-mediated secretion. Type 1 diabetes results from autoimmune β-cell destruction and absolute insulin deficiency, whereas type 2 diabetes is characterized by insulin resistance and progressive β-cell dysfunction. Type 2 diabetes accounts for approximately 90–95% of cases worldwide and is strongly linked to obesity and sedentary lifestyle, while type 1 diabetes represents 5–10% of cases. Diagnosis is based on fasting plasma glucose, oral glucose tolerance testing, and HbA1c levels. Early diagnosis, effective management, and preventive strategies are essential to reduce complications and the expanding global burden of diabetes.Downloads
References
1.International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium: IDF; 2021.
2.World Health Organization. Global Report on Diabetes. Geneva: WHO; 2016.
3.World Health Organization. Diabetes Fact Sheets and Global Health Estimates, updated 2023–2024.
4.American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl.1).
5.Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329:977–986.
6.UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. The Lancet. 1998;352:837–853.
7.Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the IDF Diabetes Atlas. Diabetes Research and Clinical Practice. 2019;157:107843.
8.Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018;14(2):88–98.
9.Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet. 2014;383(9911):69–82.
10.DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nature Reviews Disease Primers. 2015;1:15019.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India